StOPping Hypertension and imprOving Children's Lives After KidnEy TranSplantation
Launched by HANNOVER MEDICAL SCHOOL · Sep 6, 2024
Trial Information
Current as of July 25, 2025
Not yet recruiting
Keywords
ClinConnect Summary
The StOPping Hypertension and improving Children's Lives After Kidney Transplantation trial is designed to study how managing blood pressure (BP) can improve heart health in children who have received kidney transplants. This is important because many children after a transplant experience high blood pressure, which can lead to serious heart problems. The trial will involve 500 children who had their kidney transplant more than a year ago and are dealing with high blood pressure. Participants will be divided into two groups: one group will receive more intensive blood pressure management, aiming for a lower target, while the other group will follow standard care.
To join the study, children must have had a kidney transplant at least 12 months ago and have high blood pressure. However, those with certain heart conditions or recent treatment for transplant rejection will not be eligible. Throughout the trial, participants will have their blood pressure monitored closely, and their heart health will be assessed over two years. The findings from this study could help set new guidelines for blood pressure treatment in children after kidney transplants, potentially improving their long-term health and quality of life.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Kidney transplantation \>12 months ago
- • Arterial hypertension
- Exclusion Criteria:
- • Cardiac malformation
- • Treatment for a rejection episode within three months prior to inclusion
About Hannover Medical School
Hannover Medical School (Medizinische Hochschule Hannover, MHH) is a leading academic medical institution in Germany, renowned for its commitment to innovative research and high-quality clinical care. Established in 1965, MHH specializes in a wide range of medical disciplines, with a strong focus on transplantation medicine, regenerative medicine, and personalized healthcare. The institution actively participates in clinical trials to advance medical knowledge and develop cutting-edge therapies, leveraging its state-of-the-art facilities and collaborative environment. With a dedicated team of researchers, clinicians, and support staff, Hannover Medical School aims to translate scientific findings into practical applications that improve patient outcomes and enhance the overall quality of healthcare.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Patients applied
Trial Officials
Anette Melk, MD PhD
Principal Investigator
Hannover Medical School
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported